Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic ...
Company to provide additional transport stability data points in response to FDA Clinical Hold Letter CMC clearance for VIITAL™ trial anticipated in Q4 2019 Investor conference call today, Monday, September 23 at 09:30 a.m. ET NEW YORK and CLEVELAND, Sept …